Latest data on the MiSight lens show show slower myopia progression among children.
New four-year study data show a significant impact of a specialty contact lens for slowing the progression of myopia in children, including those whose treatment begins later. CooperVision presented four-year data from the Clinical Evaluation of a Dual-Focus Myopia Control 1-Day Soft Contact Lens Study, a multi-year study, during last month’s BCLA Asia conference in Singapore.
The ongoing clinical trial is assessing CooperVision MiSight, a specially designed, dual-focus myopia control one-day soft contact lens, in reducing the rate of progression of juvenile-onset myopia. The lens is commercially available as CooperVision MiSight 1 day in select countries, though MiSight is not approved in the United States.
During the fourth year of the study, researchers studied physiological changes among 100 myopic children from Singapore, Canada, England, and Portugal.
“The treatment is continuing to work for children who have been wearing MiSight contact lenses for the entire study, and their axial length progression in this last year has slowed further. This illustrates the benefits of beginning myopia management as early as possible to maximize the benefit,” said Paul Chamberlain, director of research programs for CooperVision.
After year three, myopia progression slowed in children wearing the MiSight contact lens by 59%, as measured by mean cycloplegic spherical equivalent and 52%, as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single-vision one-day contact lens.
In the fourth year, children in the original control group were refit with the myopia control lens and continued to be tracked separately. Use of the dual-focus contact lens—which has alternating visual correction and treatment zones—was effective in slowing myopia progression in both groups, according to the company. Specifically:
• There was a significant reduction in myopic progression for the previous single-vision one-day wearers, indicating that the MiSight lenses are also effective when beginning myopia management at an older age.
• There were no significant differences between groups for change in spherical equivalent refractive error and axial length over 12 months.
• Axial length growth of 0.07mm in the MiSight group and 0.06mm in the previous control group, compared to 0.10mm seen in the MiSight group in year three, represents further myopia slowing as the children age.
• There were no significant differences in myopia progression rates for two demographically matched populations in their first versus fourth years of MiSight contact lens wear.
TO FIVE BILLION
The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 2050, bringing with it near- and long-term health challenges.1 Not only does it create blurred vision, but it also increases the likelihood of conditions later in life, such as glaucoma, cataract, retinal detachment and myopic maculopathy if not addressed.
Though children benefit at whatever age the treatment is started, treatment is more effective in reducing final levels and the future risk of related vision impairment issues, said Stuart Cockerill, senior director, myopia management.
1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42.
WHERE TO FIND IT
800.341.2020 | CooperVision.com